BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

978 related articles for article (PubMed ID: 9808682)

  • 21. Metabolism of bradykinin by peptidases in the lung.
    Dragović T; Igić R; Erdös EG; Rabito SF
    Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1491-6. PubMed ID: 8389109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA; Asaad MM; Abboa-Offei BE; Smith PL; Rogers WL; Dorso CR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):708-13. PubMed ID: 8632340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potentiation of bradykinin effect by angiotensin-converting enzyme inhibition does not correlate with angiotensin-converting enzyme activity in the rat mesenteric arteries.
    Sivieri DO; Bispo-da-Silva LB; Oliveira EB; Resende AC; Salgado MC
    Hypertension; 2007 Jul; 50(1):110-5. PubMed ID: 17470724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
    Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
    J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P; Turcaud S; Meudal H; Roques BP; Fournie-Zaluski MC
    J Med Chem; 1996 Mar; 39(6):1210-9. PubMed ID: 8632427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
    Dumoulin MJ; Adam A; Rouleau JL; Gosselin H; Lamontagne D
    Can J Physiol Pharmacol; 2003 Jul; 81(7):740-6. PubMed ID: 12897822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W; Dominiak P; Dendorfer A
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of neutral endopeptidase by thiorphan does not modify coronary vascular responses to angiotensin I, angiotensin II and bradykinin in the isolated guinea pig heart.
    Kozlovski VI; Lomnicka M; Jakubowski A; Chlopicki S
    Pharmacol Rep; 2007; 59(4):421-7. PubMed ID: 17901571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
    Weckler N; Leitzbach D; Kalinowski L; Malinski T; Busch AE; Linz W
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):191-6. PubMed ID: 14608526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
    Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
    J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of angiotensin II and bradykinin inhibition in rat reduced-size liver transplantation.
    Padrissa-Altés S; Franco-Gou R; Boillot O; Serafín A; Rimola A; Arroyo V; Rodés J; Peralta C; Roselló-Catafau J
    Liver Transpl; 2009 Mar; 15(3):313-20. PubMed ID: 19242996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors.
    Georgiadis D; Beau F; Czarny B; Cotton J; Yiotakis A; Dive V
    Circ Res; 2003 Jul; 93(2):148-54. PubMed ID: 12805239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
    Trippodo NC; Fox M; Natarajan V; Panchal BC; Dorso CR; Asaad MM
    J Pharmacol Exp Ther; 1993 Oct; 267(1):108-16. PubMed ID: 8229737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK; Johnston CI; Burrell LM
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
    Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
    Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutral endopeptidase up-regulation in isolated human umbilical artery: involvement in desensitization of bradykinin-induced vasoconstrictor effects.
    Pelorosso FG; Halperin AV; Palma AM; Nowak W; Errasti AE; Rothlin RP
    J Pharmacol Exp Ther; 2007 Feb; 320(2):713-20. PubMed ID: 17085545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
    Trippodo NC; Panchal BC; Fox M
    J Pharmacol Exp Ther; 1995 Feb; 272(2):619-27. PubMed ID: 7853175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.